Have a personal or library account? Click to login
Distinct Morphological Features Predictive for Aggressiveness of Papillary Thyroid Microcarcinoma: a Study of 72 Cases and 80 Tumor Foci Cover

Distinct Morphological Features Predictive for Aggressiveness of Papillary Thyroid Microcarcinoma: a Study of 72 Cases and 80 Tumor Foci

Open Access
|Feb 2016

References

  1. 1. DeLellis RA, Williams ED. Pathology of the thyroid and parathyroid. 2004;2:57-66.
  2. 2. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014;140(4):317-322.10.1001/jamaoto.2014.1
  3. 3. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States. 1973-2002. JAMA. 2006;295(18):2164-2167.10.1001/jama.295.18.2164
  4. 4. Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics. 1980-2005. Cancer Epidemiol Biomarkers Prev. 2009;18(3):784-791.10.1158/1055-9965.EPI-08-0960
  5. 5. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No.10. http://globocan.iarc.fr. 2010.
  6. 6. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S. 1985-1995. Cancer. 1998;83(12):2638-2648.10.1002/(SICI)1097-0142(19981215)83:12<;2638::AID-CNCR31>3.0.CO;2-1
  7. 7. Sassolas G, Hafdi-Nejjari Z, Remontet Let al. Thyroid cancer: is the incidence rise abating? Eur J Endocrinol. 2009;160(1):71-79.10.1530/EJE-08-0624
  8. 8. Cătană R, Boilă A, Haifa Bet al. Time trends in thyroid pathology - a 20 year retrospective study. Acta Medica Marisiensis. 2010;56(6):534-537.
  9. 9. Hughes DT, Haymart MR, Miller BSet al. The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid. 2011;21(3):231-236.10.1089/thy.2010.0137
  10. 10. Udelsman R, Zhang Y. The epidemic of thyroid cancer in the United States: the role of endocrinologists and ultrasounds. Thyroid. 2014;24(3):472-479.10.1089/thy.2013.0257
  11. 11. Li N, Du XL, Reitzel LRet al. Impact of enhanced detection on the increase in thyroid cancer incidence in the United States: review of incidence trends by socioeconomic status within the surveillance, epidemiology, and end results registry, 1980-2008. Thyroid. 2013;23(1):103-110.10.1089/thy.2012.0392
  12. 12. Yu XM, Wan Y, Sippel RS, Chen H. Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg. 2011;254(4):653-660.10.1097/SLA.0b013e318230036d
  13. 13. Pacini F. Management of papillary thyroid microcarcinoma: primum non nocere! J Clin Endocrinol Metab. 2013;98(4):1391-1393.
  14. 14. Piana S, Ragazzi M, Tallini Get al. Papillary thyroid microcarcinoma with fatal outcome: evidence of tumor progression in lymph node metastases: report of 3 cases, with morphological and molecular analysis. Hum Pathol. 2013;44(4):556-565.10.1016/j.humpath.2012.06.019
  15. 15. Page C, Biet A, Boute Pet al. ‘Aggressive papillary’ thyroid microcarcinoma. Eur Arch Otorhinolaryngol. 2009;266(12):1959-1963.10.1007/s00405-009-0952-519294400
  16. 16. Virk RK, Van Dyke AL, Finkelstein Aet al. BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation. Mod Pathol. 2013;26(1):62-70.10.1038/modpathol.2012.15222918165
  17. 17. Virk RK, Theoharis CG, Prasad Aet al. Morphology predicts BRAF (V600E) mutation in papillary thyroid carcinoma: an interobserver reproducibility study. Virchows Arch. 2014;464(4):435-442.10.1007/s00428-014-1552-324549591
  18. 18. Niemeier LA, Kuffner AH, Song Cet al. A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer. 2012;118(8):2069-2077.10.1002/cncr.26425322964921882177
  19. 19. Rossi ED, Bizzarro T, Fadda Get al. Is morphology alone able to predict BRAF-mutated malignancies on thyroid FNAC? Virchows Arch. 2014; 465(2):247-8;10.1007/s00428-014-1607-524928715
  20. 20. Liu Z, Wang L, Yi Pet al. Risk factors for central lymph node metastasis of patients with papillary thyroid microcarcinoma: a meta-analysis. Int J Clin Exp Pathol. 2014;7(3):932-937.
  21. 21. Hsiao SJ, Nikiforov YE. Molecular approaches to thyroid cancer diagnosis. Endocr Relat Cancer. 2014;21(5):T301-T313.10.1530/ERC-14-0166416036924829266
  22. 22. Lin KL, Wang OC, Zhang XHet al. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol. 2010;17(12):3294-3300.10.1245/s10434-010-1129-620953721
  23. 23. Rossi ED, Bizzarro T, Martini Met al. Morphological parameters able to predict BRAF(V600E) -mutated malignancies on thyroid fine-needle aspiration cytology: Our institutional experience. Cancer Cytopathol. 2014;122(12):883-891.10.1002/cncy.2147525156883
  24. 24. Finkelstein A, Levy GH, Hui Pet al. Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct. Histopathology. 2012;60(7):1052-1059.10.1111/j.1365-2559.2011.04149.x22335197
DOI: https://doi.org/10.1515/amma-2015-0112 | Journal eISSN: 2668-7763 | Journal ISSN: 2668-7755
Language: English
Page range: 51 - 55
Submitted on: Aug 13, 2015
|
Accepted on: Sep 3, 2015
|
Published on: Feb 9, 2016
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2016 Adela Nechifor-Boilă, Ancuţa Elena Zahan, Oana Căpraru, Ramona Cătană, Andreea Fișus, Nicole Berger, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.